Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells

Lung Cancer

Volumn 83, Issue 1, 2014, Pages 44-50

  Furugaki, Koh ^a   Iwai, Toshiki ^a   Moriya, Yoichiro ^a   Harada, Naoki ^a   Fujimoto Ouchi, Kaori ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

EGFR TKI; Erlotinib; Mutation; Non small cell lung cancer; NSCLC; Resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CHROMOSOME 7; CHROMOSOME LOSS; CHROMOSOME MUTATION; CONTROLLED STUDY; DRUG EXPOSURE; GENE AMPLIFICATION; GENE DOSAGE; GENE ISOLATION; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

EGFR-TKI; ERLOTINIB; MUTATION; NON-SMALL CELL LUNG CANCER; NSCLC; RESISTANCE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 7; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84891736349     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.10.003     Document Type: Article

References (26)

1. Mitsudomi T. Advances in target therapy for lung cancer. Japanese Journal of Clinical Oncology 2010, 40:101-106.
2. Mitsudomi T., Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science 2007, 98:1817-1824.
3. Pao W., Miller V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. Journal of Clinical Oncology 2005, 23:2556-2568.
4. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Medicine 2005, 2:e73.
5. Balak M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clinical Cancer Research 2006, 12:6494-6501.
6. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non small cell lung cancer and acquired resistance to gefitinib. Clinical Cancer Research 2006, 12:5764-5769.
7. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
8. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science Translational Medicine 2011, 3:75ra26.
9. Yano S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor activating mutations. Cancer Research 2008, 68:9479-9487.
10. Yamashita-Kashima Y., Iijima S., Yorozu K., Furugaki K., Kurasawa M., Ohta M., et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clinical Cancer Research 2011, 17:5060-5070.
11. Furugaki K., Iwai T., Kondoh K., Moriya Y., Mori K. Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers. Oncology Letters 2010, 1:231-235.
12. Tsiatis A.C., Norris-Kirby A., Rich R.G., Hafez M.J., Gocke C.D., Eshleman J.R., et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. Journal of Molecular Diagnostics 2010, 12:425-432.
13. Seabright M. A rapid banding technique for human chromosomes. Lancet 1971, 2:971-972.
14. Brothman A.R., Persons D.L., Shaffer L.G. Nomenclature evolution: changes in the ISCN from the 2005 to the 2009 edition. Cytogenetic and Genome Research 2009, 127:1-4.
15. Kubo T., Yamamoto H., Lockwood W.W., Valencia I., Soh J., Peyton M., et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. International Journal of Cancer 2009, 124:1778-1784.
16. Costa D.B., Kobayashi S., Yeo W-L., Hamada A. Serum concentrations of erlotinib at a dose of 25mg daily. Journal of Thoracic Oncology 2010, 5:1311-1312.
17. Yamamoto N., Horiike A., Fujisaka Y., Murakami H., Shimoyama T., Yamada Y., et al. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemotherapy and Pharmacology 2008, 61:489-496.
18. Wheeler D.L., Dunn E.F., Harari P.M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nature Reviews Clinical Oncology 2010, 7:493-507.
19. Soh J., Okumura N., Lockwood W.W., Yamamoto H., Shigematsu H., Zhang W., et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS ONE 2009, 4:e7464.
20. Ekwall K., Olsson T., Turner B.M., Cranston G., Allshire R.C. Transient inhibition of histone deacetylation alters the structural and functional imprint at fission yeast centromeres. Cell 1997, 91:1021-1032.
21. Carey K.D., Garton A.J., Romero M.S., Kahler J., Thomson S., Ross S., et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Research 2006, 66:8163-8171.
22. Tabara K., Kanda R., Sonoda K., Kubo T., Murakami Y., Kawahara A., et al. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS ONE 2012, 7:e41017.
23. Dunnill M.S., Gatter K.C. Cellular heterogeneity in lung cancer. Histopathology 1986, 10:461-475.
24. Taniguchi K., Okami J., Kodama K., Higashiyama M., Kato K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Science 2008, 99:929-935.
25. Sakurada A., Lara-Guerra H., Liu N., Shepherd F.A., Tsao M.S. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. Journal of Thoracic Oncology 2008, 3:527-529.
26. Nakano H., Soda H., Takasu M., Tomonaga N., Yamaguchi H., Nakatomi K., et al. Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. Lung Cancer 2008, 60:136-140.